Neel A. Shah, Ph.D.
Affiliations: | 2012 | Pharmaceutical Systems and Policy | West Virginia University, Morgantown, WV, United States |
Area:
Epidemiology, Pharmacy, Public HealthGoogle:
"Neel Shah"Cross-listing: PHTree
Parents
Sign in to add mentorSuresh Madhavan | grad student | 2012 | West Virginia University | |
(Impact of Diabetes on Colorectal Cancer Outcomes.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Averin A, Silvia A, Lamerato L, et al. (2020) Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer |
Richert-Boe K, Lamerato L, Lyman GH, et al. (2019) Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice Blood. 134: 4688-4688 |
Lyman GH, Richert-Boe K, Lamerato L, et al. (2019) Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice Blood. 134: 5854-5854 |
Bonafede M, Sapra S, Shah N, et al. (2018) Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache |
Bonafede M, Cai Q, Cappell K, et al. (2017) Factors Associated with Direct Health Care Costs Among Patients with Migraine. Journal of Managed Care & Specialty Pharmacy. 23: 1169-1176 |
Gu T, Shah N, Deshpande G, et al. (2016) Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes |
Gu T, Deshpande G, Tang D, et al. (2016) one-year biologic cost per patient with psoriatic diseases in a managed care population : 3564 Journal of the American Academy of Dermatology. 74 |
Sauer BC, Teng CC, He T, et al. (2015) Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Journal of Medical Economics. 1-34 |
Wu N, Bhurke S, Shah N, et al. (2015) Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. Clinicoeconomics and Outcomes Research : Ceor. 7: 257-66 |
Bonafede M, Johnson BH, Princic N, et al. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics. 18: 376-89 |